MedTrace Logo

Alzheimer's Disease Biomarkers in Cerebrospinal Fluid in Insulin-resistant Men

NCT02010476 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2016-05-12

No results posted yet for this study

Summary

Type 2 diabetes mellitus has been associated with an about 2-fold increase in risk of Alzheimer's disease (AD). Patients with AD have been reported to have reduced insulin sensitivity. It may be hypothesized that, compared to insulin sensitive subjects otherwise similar in general health and body habitus, insulin resistant subjects are more likely to have cerebrospinal fluid (CSF) indicators of incipient AD pathology, abnormalities in CSF peptides related to insulin signaling and glucose homeostasis, and possibly other metabolites that are associated with a risk of AD. The objective of this study is to examine the relation of insulin resistance and the concentrations of CSF biomarkers. The results of this study may be useful in the detection of the subjects who are at risk for cognitive decline and AD.

Conditions

Sponsors & Collaborators

  • King's College London

    collaborator OTHER

  • Sahlgrenska University Hospital

    collaborator OTHER

  • Janssen Pharmaceutica

    collaborator INDUSTRY

  • University of Eastern Finland

    lead OTHER

Principal Investigators

  • Hilkka Soininen, Professor · University of Eastern Finland

Eligibility

Min Age
55 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02010476 on ClinicalTrials.gov